MXPA05011524A - Acidos carboxilicos sustituidos. - Google Patents
Acidos carboxilicos sustituidos.Info
- Publication number
- MXPA05011524A MXPA05011524A MXPA05011524A MXPA05011524A MXPA05011524A MX PA05011524 A MXPA05011524 A MX PA05011524A MX PA05011524 A MXPA05011524 A MX PA05011524A MX PA05011524 A MXPA05011524 A MX PA05011524A MX PA05011524 A MXPA05011524 A MX PA05011524A
- Authority
- MX
- Mexico
- Prior art keywords
- useful
- compounds
- carboxylic acids
- treatment
- substituted carboxylic
- Prior art date
Links
- 150000001735 carboxylic acids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 1
- 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46705703P | 2003-04-30 | 2003-04-30 | |
| PCT/US2004/011371 WO2004099168A2 (en) | 2003-04-30 | 2004-04-14 | Substituted carboxylic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05011524A true MXPA05011524A (es) | 2006-03-21 |
Family
ID=33435014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05011524A MXPA05011524A (es) | 2003-04-30 | 2004-04-14 | Acidos carboxilicos sustituidos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7358364B2 (enExample) |
| EP (1) | EP1620420A2 (enExample) |
| JP (1) | JP2006525329A (enExample) |
| KR (1) | KR20060006953A (enExample) |
| CN (1) | CN1812977A (enExample) |
| AU (1) | AU2004236173B2 (enExample) |
| BR (1) | BRPI0409914A (enExample) |
| CA (1) | CA2523714A1 (enExample) |
| EA (1) | EA200501710A1 (enExample) |
| MX (1) | MXPA05011524A (enExample) |
| NO (1) | NO20054957L (enExample) |
| WO (1) | WO2004099168A2 (enExample) |
| ZA (1) | ZA200509631B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006525329A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 置換カルボン酸類 |
| US7582773B2 (en) * | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
| FR2869615B1 (fr) * | 2004-05-03 | 2007-11-16 | Merck Sante Soc Par Actions Si | Derives de l'acide butanoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et leurs applications therapeutiques |
| JP2008506702A (ja) | 2004-07-14 | 2008-03-06 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎を治療するための方法 |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| NZ553329A (en) | 2004-07-22 | 2010-09-30 | Ptc Therapeutics Inc | Thienopyridines for treating hepatitis C |
| JP2008518937A (ja) * | 2004-10-28 | 2008-06-05 | ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー | 置換カルボン酸 |
| JP2008520692A (ja) * | 2004-11-18 | 2008-06-19 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 複素環置換カルボン酸 |
| CN102775396B (zh) | 2005-11-08 | 2014-10-08 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的杂环调控剂 |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| WO2007109851A1 (en) | 2006-03-29 | 2007-10-04 | Velacor Therapeutics Pty Ltd | Treatment of neurodegenerative diseases |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| WO2008119109A1 (en) | 2007-03-29 | 2008-10-09 | Velacor Therapeutics Pty Ltd | Treatment of neurological disorders |
| JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒのモジュレーター |
| EP2231606B1 (en) | 2007-12-07 | 2013-02-13 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| NZ614151A (en) | 2007-12-07 | 2015-04-24 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| ES2647531T3 (es) | 2008-02-28 | 2017-12-22 | Vertex Pharmaceuticals Incorporated | Derivados de heteroarilo como moduladores de CFTR |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| ES3017582T3 (en) | 2010-04-07 | 2025-05-13 | Vertex Pharma | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof |
| RU2538964C1 (ru) | 2010-12-17 | 2015-01-10 | Мицубиси Танабе Фарма Корпорейшн | Соединение с последовательной арициклической структурой, обладающее активностью ингибирования ацилкофермента а: диацилглицеринацилтрансферазы (dgat1) |
| EP2862856B1 (en) | 2012-06-15 | 2018-08-01 | Mitsubishi Tanabe Pharma Corporation | Imidazole and triazole compounds as dgat-1 inhibitors |
| ES2707961T3 (es) * | 2013-07-11 | 2019-04-08 | Bristol Myers Squibb Co | Inhibidores de IDO |
| CN105848657B (zh) | 2013-11-12 | 2020-05-22 | 沃泰克斯药物股份有限公司 | 制备用于治疗cftr介导的疾病的药物组合物的方法 |
| JP2017509665A (ja) | 2014-04-03 | 2017-04-06 | バイエル ファーマ アクチエンゲゼルシャフト | 気道疾患治療のための２，５−ジ置換されたシクロペンタンカルボン酸類 |
| WO2015150362A2 (de) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | Chirale 2,5-disubstituierte cyclopentancarbonsäure-derivate und ihre verwendung |
| EP3126339A1 (de) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung |
| SI3221692T1 (sl) | 2014-11-18 | 2021-11-30 | Vertex Pharmaceuticals Inc. | Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo |
| KR102147712B1 (ko) * | 2015-01-20 | 2020-08-25 | 시노라 게엠베하 | 유기 분자, 특히 광전자 구성성분에 사용하기 위한 유기 분자 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1176339A (en) * | 1965-12-27 | 1970-01-01 | Lilly Co Eli | Hydrocinnamic Acid Compounds and Processes for making them |
| IL30498A0 (en) | 1967-08-14 | 1968-10-24 | Merck & Co Inc | Process for the preparation of phenyl salicylic acid compounds and intermediates used therein |
| CH542806A (de) * | 1967-10-06 | 1973-10-15 | Ciba Geigy Ag | Verfahren zur Herstellung einer neuen Aryloxyalkansäure und ihrer Salze |
| CH499526A (de) * | 1968-06-06 | 1970-11-30 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Tetrazolderivaten |
| US3755603A (en) * | 1970-07-01 | 1973-08-28 | Syntex Corp | Biphenylyloxyacetic acids in pharmaceutical compositions |
| DE2205732A1 (de) * | 1972-02-08 | 1973-08-16 | Thomae Gmbh Dr K | Neue 4-(4-biphenylyl)-butensaeurederivate |
| NL7301246A (enExample) * | 1972-02-14 | 1973-08-16 | ||
| DE2358789A1 (de) * | 1973-02-07 | 1975-06-05 | Merck Patent Gmbh | Hydratropasaeure-derivate und verfahren zu ihrer herstellung |
| FR2457275A1 (fr) | 1979-05-21 | 1980-12-19 | Fabre Sa Pierre | Acides p-biphenyl-4 methyl-2 buten-3 oiques utiles dans le traitement des rhumatismes |
| TW268952B (enExample) | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
| US5789434A (en) * | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| US5886022A (en) * | 1995-06-05 | 1999-03-23 | Bayer Corporation | Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors |
| JP3628335B2 (ja) | 1996-01-23 | 2005-03-09 | 塩野義製薬株式会社 | スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤 |
| EP1288206B1 (en) | 1996-04-12 | 2008-09-17 | G.D. Searle LLC | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors |
| AU2381497A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| IT1290679B1 (it) * | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
| WO1999011255A1 (en) | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
| CO5011105A1 (es) | 1997-12-22 | 2001-02-28 | Novartis Ag | Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion |
| AU2713699A (en) * | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| AU774929B2 (en) * | 1998-03-31 | 2004-07-15 | Institutes For Pharmaceutical Discovery, Llc, The | Substituted indolealkanoic acids |
| WO1999058520A1 (en) * | 1998-05-12 | 1999-11-18 | American Home Products Corporation | Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia |
| ATE229015T1 (de) * | 1998-05-12 | 2002-12-15 | Wyeth Corp | Zur behandlung von insulin-resistenz und hyperglycemie geeignete biphenyl-oxo-essigsäuren |
| CN1308619A (zh) | 1998-05-12 | 2001-08-15 | 美国家用产品公司 | (2－酰氨基噻唑－4－基)乙酸衍生物 |
| US6232322B1 (en) * | 1998-05-12 | 2001-05-15 | American Home Products Corporation | Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
| US6221902B1 (en) * | 1998-05-12 | 2001-04-24 | American Home Products Corporation | Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia |
| WO1999061410A1 (en) * | 1998-05-12 | 1999-12-02 | American Home Products Corporation | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia |
| ATE368037T1 (de) | 1999-04-28 | 2007-08-15 | Sanofi Aventis Deutschland | Di-aryl-säurederivate als ppar rezeptor liganden |
| IL147197A0 (en) * | 1999-06-25 | 2002-08-14 | Inst For Pharm Discovery Inc | Substituted phenoxy acetic acids |
| AU4398801A (en) * | 2000-03-22 | 2001-10-03 | Banyu Pharmaceutical Co., Ltd. | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| WO2001083464A1 (en) | 2000-04-21 | 2001-11-08 | Shionogi & Co., Ltd. | Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders |
| EP1288199A4 (en) | 2000-04-28 | 2005-10-12 | Shionogi & Co | INHIBITORS OF MMP-12 |
| AU2001248820A1 (en) | 2000-04-28 | 2001-11-12 | Shionogi And Co., Ltd. | Thiazole and oxazole derivatives |
| WO2002004459A1 (en) | 2000-07-07 | 2002-01-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| DE60128475T2 (de) | 2000-07-25 | 2008-02-07 | Merck & Co., Inc. | N-substituierte indole mit anwendung in der behandlung von diabetes |
| US6472545B2 (en) * | 2000-08-29 | 2002-10-29 | Abbott Laboratories | Protein tyrosine phosphatase inhibitors |
| EP1331224A4 (en) | 2000-09-29 | 2004-03-17 | Shionogi & Co | THIAZOLE AND OXAZOLE DERIVATIVES |
| WO2002064094A2 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| CN100344616C (zh) | 2001-06-12 | 2007-10-24 | 维尔斯达医疗公司 | 用于治疗代谢失调的化合物 |
| DE10150172A1 (de) | 2001-10-11 | 2003-04-30 | Morphochem Ag | Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren |
| JP4219810B2 (ja) | 2001-10-26 | 2009-02-04 | 塩野義製薬株式会社 | Ｍｍｐ阻害作用を有するスルホンアミド誘導体 |
| CA2469228A1 (en) * | 2001-12-03 | 2003-06-12 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| EP1539137B1 (en) | 2002-07-30 | 2010-05-26 | Merck Sharp & Dohme Corp. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| DK1537078T3 (da) | 2002-08-29 | 2010-08-02 | Merck Sharp & Dohme | Indoler med anti-diabetisk aktivitet |
| ATE384526T1 (de) | 2003-04-14 | 2008-02-15 | Inst For Pharm Discovery Inc | N-(((((1,3-thiazol-2- yl)amino)carbonyl)phenyl)sulphonyl)phenylalanin derivate und verwandte verbindungen zur behandlung von diabetes |
| JP2006525329A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 置換カルボン酸類 |
| WO2005063222A1 (ja) | 2003-12-26 | 2005-07-14 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
| TW200630327A (en) | 2004-10-28 | 2006-09-01 | Inst For Pharm Discovery Inc | Substituted phenylalkanoic acids |
-
2004
- 2004-04-14 JP JP2006509981A patent/JP2006525329A/ja active Pending
- 2004-04-14 MX MXPA05011524A patent/MXPA05011524A/es not_active Application Discontinuation
- 2004-04-14 EA EA200501710A patent/EA200501710A1/ru unknown
- 2004-04-14 EP EP04760538A patent/EP1620420A2/en not_active Withdrawn
- 2004-04-14 CN CNA2004800184160A patent/CN1812977A/zh active Pending
- 2004-04-14 WO PCT/US2004/011371 patent/WO2004099168A2/en not_active Ceased
- 2004-04-14 AU AU2004236173A patent/AU2004236173B2/en not_active Ceased
- 2004-04-14 KR KR1020057020613A patent/KR20060006953A/ko not_active Withdrawn
- 2004-04-14 CA CA002523714A patent/CA2523714A1/en not_active Abandoned
- 2004-04-14 US US10/823,842 patent/US7358364B2/en not_active Expired - Fee Related
- 2004-04-14 BR BRPI0409914-1A patent/BRPI0409914A/pt not_active IP Right Cessation
-
2005
- 2005-10-25 NO NO20054957A patent/NO20054957L/no not_active Application Discontinuation
- 2005-11-29 ZA ZA200509631A patent/ZA200509631B/en unknown
-
2008
- 2008-04-15 US US12/103,082 patent/US20090082392A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20054957L (no) | 2006-01-23 |
| EA200501710A1 (ru) | 2006-06-30 |
| US20090082392A1 (en) | 2009-03-26 |
| WO2004099168A3 (en) | 2005-02-24 |
| AU2004236173B2 (en) | 2008-07-03 |
| BRPI0409914A (pt) | 2006-04-25 |
| WO2004099168A2 (en) | 2004-11-18 |
| NO20054957D0 (no) | 2005-10-25 |
| US20040266788A1 (en) | 2004-12-30 |
| CN1812977A (zh) | 2006-08-02 |
| EP1620420A2 (en) | 2006-02-01 |
| AU2004236173A1 (en) | 2004-11-18 |
| KR20060006953A (ko) | 2006-01-20 |
| ZA200509631B (en) | 2007-02-28 |
| CA2523714A1 (en) | 2004-11-18 |
| US7358364B2 (en) | 2008-04-15 |
| JP2006525329A (ja) | 2006-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05010937A (es) | Derivados de fenilalanina n-(1,3-tiazol-2-il)amino)carbonil)fenil)sulfonil) y compuestos relacionados para el tratamiento de diabetes. | |
| MXPA05011524A (es) | Acidos carboxilicos sustituidos. | |
| MXPA05011539A (es) | Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b. | |
| TW200630327A (en) | Substituted phenylalkanoic acids | |
| MXPA05011537A (es) | Acidos aminocaboxilicos sustituidos. | |
| MXPA05011536A (es) | Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b. | |
| MXPA05011523A (es) | Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas. | |
| WO2006055708A3 (en) | Heterocycle substituted carboxylic acids for the treatment of diabetes | |
| WO2008074997A8 (en) | Pyridine benzamides and pyrazine benzamides used as pkd inhibitors | |
| WO2006055625A3 (en) | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors | |
| TW200630354A (en) | Substituted amino carboxylic acids | |
| CR20240003A (es) | Restos de administración terapéutica novedosos y usos de estos | |
| WO2008033932A3 (en) | Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors | |
| WO2008033455A3 (en) | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors | |
| IL192557A (en) | Imidazole derivatives are conserved and used as ptpase inhibitors | |
| DE602004017174D1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
| DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
| UA92636C2 (en) | Tetrahydro-pyrimidoazepines as modulators of trpv1 | |
| WO2007125331A3 (en) | Amino-ethyl-amino-aryl (aeaa) compounds and their use | |
| TW200631949A (en) | Substituted carboxylic acids | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten | |
| IL175358A0 (en) | 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease | |
| WO2006138589A3 (en) | Opioid receptor ligands | |
| IL175357A0 (en) | 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease | |
| DE602004013770D1 (de) | Diagnostik- und therapie- verfahren von mit pils verbundenen krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |